Clinical medicine of the future is poised to use an individual’s genomic data to predict disease risk and guide clinical care. The treatment of cigarette smoking and tobacco use disorder represents a prime area for genomics implementation. The genes CHRNA5 and CYP2A6 are strong genomic contributors that alter the risk of heaviness of smoking, tobacco use disorder, and smoking-related diseases in humans. These biomarkers have proven analytical and clinical validity, and evidence for their clinical utility continues to grow. We propose that these biomarkers harbor the potential of enabling the identification of elevated disease risk in smokers, personalizing smoking cessation treatments, and motivating behavioral changes. We must prepare for the integration of genomic applications into clinical care of patients who smoke.

未来的临床医学将准备使用个人的基因组数据来预测疾病风险并指导临床护理。吸烟和烟草使用失调的治疗是基因组学实施的主要领域。基因CHRNA5和CYP2A6是改变人类吸烟重症，烟草使用失调和吸烟相关疾病风险的强大基因组贡献者。这些生物标记物已被证明具有分析和临床有效性，并且其临床效用的证据不断增长。我们认为，这些生物标记物具有识别吸烟者中疾病风险升高，个性化戒烟治疗以及促进行为改变的潜力。我们必须为将基因组学应用整合到吸烟患者的临床护理做好准备。